|[July 11, 2014]
Research and Markets: India Coronary Stent Market-Potentials and Growth Forecast to 2019 With Abbott Vascular & Boston Scientific Leading the Way
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/v54tn2/india_coronary)
has announced the addition of the "India
Coronary Stent Market-Potentials and Growth Forecast to 2019"
report to their offering.
India Coronary Stent Market Would Continue to Grow in Double Digits and
Abbott Vascular to Lead the Market
The coronary stent market in India was valued around $450 million in
2012 and it has grown at an impressive rate of 22% (2005-2012) backed by
a rise in PCIs (Percutaneous Coronary Intervention) which is resulted
from a surge in cardiovascular disease (CVD), an improvement in
healthcare infrastructure and services and an increase in disposable
income. An increasing penetration of DES, which is aboe 90%, has also
boosted the market.
The market is lead by Abbott Vascular, followed by Boston Scientific.
Other key players operating in the segment are Medtronic, Inc.,
Biotronik, Sahajanand Medical Technologies, Meril Life Sciences and
Translumina Therapeutics. Johnson and Johnson's Cordis stopped selling
its stents from 20011. Cordis's market was grabbed by Abbott, Medtronic
and other players. Bioabsorbable stent ABSORB, which was recently
launched by Abbott Vascular, has garnered a considerable traction among
the medical fraternity despite its high cost compared with other stents
available in the market. The patients opting for ABSORB are financially
sound or have either health insurance or are entitled for reimbursement.
Abbott is aggressively chasing the market through a direct-to-consumer
The coronary stent market in the country will continue to grow at a
faster pace due to new and upcoming private hospitals, government
initiatives to improve healthcare access, an increasing number of
interventional cardiologists, an explosion of healthcare insurance and a
growth in usage of high value bioabsorbable stents. The anticipated
progression can be attributed to growth in elderly population, improved
life expectancy, lifestyle diseases and associated complications like
diabetes, hypertension and obesity.
Boston Scientific Corporation
Meril Life Sciences
For more information visit http://www.researchandmarkets.com/research/v54tn2/india_coronary
[ Back To TMCnet.com's Homepage ]